4.7 Article

International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma

Journal

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ijrobp.2019.06.2540

Keywords

-

Ask authors/readers for more resources

Purpose: The treatment of nasopharyngeal carcinoma requires high radiation doses. The balance of the risks of local recurrence owing to inadequate tumor coverage versus the potential damage to the adjacent organs at risk (OARs) is of critical importance. With advancements in technology, high target conformality is possible. Nonetheless, to achieve the best possible dose distribution, optimal setting of dose targets and dose prioritization for tumor volumes and various OARs is fundamental. Radiation doses should always be guided by the As Low As Reasonably Practicable principle. There are marked variations in practice. This study aimed to develop a guideline to serve as a global practical reference. Methods and Materials: A literature search on dose tolerances and normal-tissue complications after treatment for nasopharyngeal carcinoma was conducted. In addition, published guidelines and protocols on dose prioritization and constraints were reviewed. A text document and preliminary set of variants was circulated to a panel of international experts with publications or extensive experience in the field. An anonymized voting process was conducted to rank the proposed variants. A summary of the initial voting and different opinions expressed by members were then recirculated to the whole panel for review and reconsideration. Based on the comments of the panel, a refined second proposal was recirculated to the same panel. The current guideline was based on majority voting after repeated iteration for final agreement. Results: Variation in opinion among international experts was repeatedly iterated to develop a guideline describing appropriate dose prioritization and constraints. The percentage of final agreement on the recommended parameters and alternative views is shown. The rationale for the recommendations and the limitations of current evidence are discussed. Conclusions: Through this comprehensive review of available evidence and interactive exchange of vast experience by international experts, a guideline was developed to provide a practical reference for setting dose prioritization and acceptance criteria for tumor volumes and OARs. The final decision on the treatment prescription should be based on the individual clinical situation and the patient's acceptance of optimal balance of risk. (C) 2019 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Neus Baste, Prakash Neupane, Ase Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, Danny Rischin

Summary: The study presents a post hoc analysis of the long-term efficacy and progression-free survival in recurrent/metastatic head and neck squamous cell carcinoma patients treated with pembrolizumab and pembrolizumab-chemotherapy as next-line therapy. The results demonstrate favorable clinical efficacy and progression-free survival with pembrolizumab and pembrolizumab-chemotherapy in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) >= 20, CPS >= 1, and total populations. Subsequent treatments after pembrolizumab-based therapy also showed good efficacy.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions

W. K. Jacky Lam, Ann D. King, Jacob A. Miller, Zhiwei Liu, Kelly J. Yu, Melvin L. K. Chua, Brigette B. Y. Ma, Ming Yuan Chen, Benjamin A. Pinsky, Pei-Jen Lou, John K. S. Woo, Wan-Lun Hsu, Julia Simon, Denise L. Doolan, Tim Waterboer, Edwin P. Hui, Hui Li, Raymond K. Tsang, Kenneth C. W. Wong, Julian P. Goh, Alexander C. Vlantis, Qi Yong Ai, Lun M. Wong, Victor Abdullah, Jin Ching Lin, Chien-Jen Chen, Ruth M. Pfeiffer, Quynh-Thu Le, Anne W. M. Lee, Mingfang Ji, Sumei Cao, Jun Ma, Anthony T. C. Chan, K. C. Allen Chan, Allan Hildesheim

Summary: A meeting of experts in November 2021 discussed the performance and cost-effectiveness of EBV-based approaches for screening early stage nasopharyngeal carcinoma. Both serum EBV antibody and plasma EBV DNA testing methods were found to be favorable. Additionally, the use of MRI was recommended to increase the sensitivity of NPC detection without greatly impacting the cost-effectiveness of the screening program.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Oncology

Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial

Eric J. Sherman, Jonathan Harris, Keith C. Bible, Ping Xia, Ronald A. Ghossein, Christine H. Chung, Nadeem Riaz, G. Brandon Gunn, Robert L. Foote, Sue S. Yom, Stuart J. Wong, Shlomo A. Koyfman, Michael F. Dzeda, David A. Clump, Saad A. Khan, Manisha H. Shah, Kevin Redmond, Pedro A. Torres-Saavedra, Quynh-Thu Le, Nancy Y. Lee

Summary: This study is the largest randomized anaplastic thyroid cancer study that has been completed, showing the feasibility and safety of the treatment combination. Although no significant improvement in overall survival was observed in the pazopanib group, hypothesis-generating data were generated that may warrant further investigation.

LANCET ONCOLOGY (2023)

Review Oncology

Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?

Robert I. Haddad, Kevin Harrington, Makoto Tahara, Petr Szturz, Christophe Le Tourneau, Satu Salmio, Marcis Bajars, Nancy Y. Lee

Summary: For the last 20 years, cisplatin-based chemoradiotherapy has been the standard treatment for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) patients at high risk of recurrence. However, many patients are ineligible for this treatment due to various reasons. The criteria for cisplatin ineligibility, including age and renal impairment, are still debated. The proportion of cisplatin ineligible patients with resected LA SCCHN remains unclear. This review discusses cisplatin ineligibility considerations, limited clinical evidence, and ongoing clinical trials for alternative treatment options.

CANCER TREATMENT REVIEWS (2023)

Article Oncology

An efficient strategy to select head and neck cancer patients for adaptive radiotherapy

Yong Gan, Johannes A. Langendijk, Arjen van der Schaaf, Lisa van den Bosch, Edwin Oldehinkel, Zhixiong Lin, Stefan Both, Charlotte L. Brouwer

Summary: This study aimed to develop an efficient strategy to select candidates for adaptive radiotherapy (ART) in the first two weeks of head and neck cancer (HNC) radiotherapy. By retrospectively analyzing data from 110 HNC patients, it was found that using the difference between planning and actual dose and clinical relevance as cut-off points could identify potential candidates for ART. The proposed strategy showed improved sensitivity, specificity, and predictive values.

RADIOTHERAPY AND ONCOLOGY (2023)

Article Oncology

Validation of the 18F-FDG PET image biomarker model predicting late xerostomia after head and neck cancer radiotherapy

Yan Li, Nanna Maria Sijtsema, Suzanne Petronella Maria de Vette, Roel Johannes Henricus Marinus Steenbakkers, Fan Zhang, Walter Noordzij, Lisa Van den Bosch, Johannes Albertus Langendijk, Lisanne Vania van Dijk

Summary: This study aimed to validate the predictive ability of PET image biomarkers (PET-IBMs) for late-xerostomia after radiotherapy. The results showed that the PET-P90 model and PET-Mean model performed well in predicting late-xerostomia, and their performance was better than the base model.

RADIOTHERAPY AND ONCOLOGY (2023)

Editorial Material Oncology

Think big-think BiGART. The 21st Acta Oncologica Symposium-BiGART 2023

Jesper Grau Eriksen, Birgitte Vrou Offersen, Morten Hoyer, Cai Grau, Jens Overgaard

ACTA ONCOLOGICA (2023)

Article Oncology

Changes in Sexuality and Sexual Dysfunction over Time in the First Two Years after Treatment of Head and Neck Cancer

Margot A. Stone, Birgit I. Lissenberg-Witte, Remco de Bree, Jose A. Hardillo, Femke Lamers, Johannes A. Langendijk, C. Rene Leemans, Robert P. Takes, Femke Jansen, Irma M. Verdonck-de Leeuw

Summary: This study investigated changes in sexuality and sexual dysfunction in head and neck cancer patients in the first two years after treatment, specifically looking at the impact of different treatments. Results showed that patients treated with chemoradiation experienced a deterioration in sexuality and sexual dysfunction, with differences observed between men and women. Men reported changes in erectile function, orgasm, satisfaction with intercourse, and overall satisfaction, while women reported changes in desire, arousal, and orgasm. These findings provide important information for improving sexual care for head and neck cancer patients.

CANCERS (2023)

Article Oncology

Comparison of computed tomography image features extracted by radiomics, self-supervised learning and end-to-end deep learning for outcome prediction of oropharyngeal cancer

Baoqiang Ma, Jiapan Guo, Hung Chu, Lisanne V. van Dijk, Peter M. A. van Ooijen, Johannes A. Langendijk, Stefan Both, Nanna M. Sijtsema

Summary: This study compared the prediction performance of radiomics, self-supervised learning, and end-to-end deep learning for OPSCC patients after (chemo)radiotherapy. The results showed that features extracted using self-supervised learning had the best internal prediction performance, while radiomics features had better external generalizability.

PHYSICS & IMAGING IN RADIATION ONCOLOGY (2023)

Article Oncology

Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis

Claire Petit, Anne Lee, Jun Ma, Benjamin Lacas, Wai Tong Ng, Anthony T. C. Chan, Ruey-Long Hong, Ming-Yuan Chen, Lei Chen, Wen-Fei Li, Pei-Yu Huang, Terence Tan, Roger K. C. Ngan, Guopei Zhu, Hai-Qiang Mai, Edwin P. Hui, George Fountzilas, Li Zhang, Alexandra Carmel, Dora L. W. Kwong, James Moon, Jean Bourhis, Anne Auperin, Jean-Pierre Pignon, Pierre Blanchard

Summary: This study updated the evaluation of chemotherapy for nasopharynx carcinoma through a network meta-analysis. The results showed that the addition of induction chemotherapy or adjuvant chemotherapy to chemoradiotherapy improved overall survival for patients with non-metastatic nasopharyngeal carcinoma compared to chemoradiotherapy alone.

LANCET ONCOLOGY (2023)

Article Oncology

External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts

M. Berbee, C. T. Muijs, F. E. M. Voncken, L. Wee, M. Sosef, B. van Etten, J. W. van Sandick, F. A. R. M. Warmerdam, J. J. de Haan, E. Oldehinkel, J. M. van Dieren, L. Boersma, J. A. Langendijk, A. van der Schaaf, J. B. Reitsma, E. Schuit

Summary: This study externally validated a model for predicting 2-year total mortality in lung cancer patients in esophageal cancer patients. The intercept and/or slope of the original model needed adjustment to achieve good performance in esophageal cancer patients.

RADIOTHERAPY AND ONCOLOGY (2024)

Article Oncology

Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses

Elaine Limkin, Pierre Blanchard, Benjamin Lacas, Jean Bourhis, Mahesh Parmar, Lisa Licitra, Quynh-Thu Le, Sue S. Yom, Catherine Fortpied, Johannes Langendijk, Jan B. Vermorken, Jacques Bernier, Jens Overgaard, Jonathan Harris, Jean-Pierre Pignon, Anne Auperin

Summary: This study investigated the impact of season of radiotherapy on the outcomes of head and neck squamous cell cancer patients. The results showed that the season of radiotherapy did not have any significant effect on patient outcomes.

RADIOTHERAPY AND ONCOLOGY (2024)

Article Oncology

Mental healthcare utilization among head and neck cancer patients: A longitudinal cohort study

Femke Jansen, Birgit I. Lissenberg-Witte, Jose A. Hardillo, Robert P. Takes, Remco de Bree, Femke Lamers, Johannes A. Langendijk, C. Rene Leemans, Irma M. Verdonck-de Leeuw

Summary: Utilization of mental healthcare among head and neck cancer patients is limited and is associated with psychological symptoms, need for mental healthcare, and sociodemographic, clinical, and personal factors.

PSYCHO-ONCOLOGY (2023)

Article Dentistry, Oral Surgery & Medicine

Site-specific radiation dosage and implant survival in oral cancer patients: A cohort study

Jamie M. Alberga, Arjan Vissink, Anke Korfage, Sebastiaan A. H. J. de Visscher, Max J. H. Witjes, Johannes A. Langendijk, Gerry M. Raghoebar

Summary: By assessing radiation dosages on implant regions, it was found that an implant-specific D-mean higher than 50 Gy is associated with more peri-implant bone loss and eventual implant loss.

ORAL DISEASES (2023)

No Data Available